Compare LEA & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEA | DNTH |
|---|---|---|
| Founded | 1917 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.1B |
| IPO Year | 1994 | 2018 |
| Metric | LEA | DNTH |
|---|---|---|
| Price | $131.32 | $91.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $132.21 | $121.00 |
| AVG Volume (30 Days) | 488.4K | ★ 834.4K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 8.15 | N/A |
| Revenue | ★ $23,259,100,000.00 | $2,036,000.00 |
| Revenue This Year | $2.50 | N/A |
| Revenue Next Year | $3.12 | $29.48 |
| P/E Ratio | $15.83 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $81.62 | $16.77 |
| 52 Week High | $142.84 | $96.50 |
| Indicator | LEA | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 64.22 | 62.69 |
| Support Level | $115.26 | $33.94 |
| Resistance Level | $142.84 | N/A |
| Average True Range (ATR) | 3.05 | 4.00 |
| MACD | 1.17 | -0.56 |
| Stochastic Oscillator | 96.92 | 59.35 |
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.